Matching trials
2,411 results
- Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Aflibercept for Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept for Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00437034).
- AGAVE-201Independent statistical analysis of A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Aging and Estrogen on Cortical Function: Complete Statistical AnalysisIndependent statistical analysis of Aging and Estrogen on Cortical Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01268046).
- AGN-199201 for the Treatment of Erythema With Rosacea: Complete Statistical AnalysisIndependent statistical analysis of AGN-199201 for the Treatment of Erythema With Rosacea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01735201).
- AHIndependent statistical analysis of A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ALCIndependent statistical analysis of Acetyl-L-Carnitine in the Treatment of Septic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00592488).
- Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01226420).
- Alemtuzumab + Rituximab Consolidation in CLL: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab + Rituximab Consolidation in CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00771602).
- Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361711).
- ALFSG-MBTIndependent statistical analysis of 13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: primary endpoint…
- Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Alkali Therapy in Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Alkali Therapy in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01452412).
- Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ALLEGRO-2b/3Independent statistical analysis of PF-06651600 for the Treatment of Alopecia Areata: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03732807).
- Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs: Complete Statistical AnalysisIndependent statistical analysis of Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs: primary endpoint results, effect estimate with confidence interval, sample-size…
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Stem Cell Transplant for CLL: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant for CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01629511).
- Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ALTISSIMOIndependent statistical analysis of A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- AMARANTHComplete statistical analysis of the AMARANTH phase 2/3 trial of lanabecestat in early Alzheimer's disease, including trial design, primary and secondary endpoint results, ANCOVA and mixed-effects methodology, safety, and statistical interpretation.
- AmatuximabIndependent statistical analysis of An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AMEERA-3Independent statistical analysis of Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment: Complete Statistical AnalysisIndependent statistical analysis of Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02317783).
- An Alternative Dosing Schedule of Varenicline for Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of An Alternative Dosing Schedule of Varenicline for Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00835900).
- An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma: primary endpoint results, effect estimate with…
- An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung:…
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge: Complete Statistical AnalysisIndependent statistical analysis of An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection: Complete Statistical AnalysisIndependent statistical analysis of An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study: Complete Statistical AnalysisIndependent statistical analysis of An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus: Complete Statistical AnalysisIndependent statistical analysis of An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease: Complete Statistical AnalysisIndependent statistical analysis of An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia: Complete Statistical AnalysisIndependent statistical analysis of An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease: primary endpoint results, effect estimate…
- An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.: Complete Statistical AnalysisIndependent statistical analysis of An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma: Complete Statistical AnalysisIndependent statistical analysis of An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma: primary endpoint results, effect…